{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:14:41Z","timestamp":1787163281470,"version":"build-2736575974"},"reference-count":69,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.taap.2012.06.007","type":"journal-article","created":{"date-parts":[[2012,6,18]],"date-time":"2012-06-18T05:57:40Z","timestamp":1339999060000},"page":"171-183","source":"Crossref","is-referenced-by-count":35,"title":["The role of the anaesthetised guinea-pig in the preclinical cardiac safety evaluation of drug candidate compounds"],"prefix":"10.1016","volume":"263","author":[{"given":"Louise","family":"Marks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Borland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Philp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Ewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Lain\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Skinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Kirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Valentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2012.06.007_bb0005","first-page":"59","article-title":"Correlation of the hemodynamic and pharmacokinetic profile of intravenous milrinone in the anaesthetised dog","volume":"267","author":"Alousi","year":"1984","journal-title":"Arch. Int. Pharmacodyn."},{"key":"10.1016\/j.taap.2012.06.007_bb0340","author":"Anon"},{"key":"10.1016\/j.taap.2012.06.007_bb0345","author":"Anon"},{"issue":"9","key":"10.1016\/j.taap.2012.06.007_bb0020","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1517\/13543784.17.9.1331","article-title":"Keeping checkpoint kinases in line: new selective inhibitors in clinical trials","volume":"17","author":"Ashwell","year":"2008","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.taap.2012.06.007_bb0025","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1432-1033.1991.tb15795.x","article-title":"Two functional NaqrKq-ATPase isoforms in the left ventricle of the guinea pig heart","volume":"196","author":"Berrebi-Bertrand","year":"1991","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.taap.2012.06.007_bb0030","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/415198a","article-title":"Cardiac excitation\u2013contraction coupling","volume":"415","author":"Bers","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.taap.2012.06.007_bb0035","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1476-7120-3-27","article-title":"Myocardial contractility in the echo lab: molecular, cellular and pathophysiological basis","volume":"3","author":"Bombardini","year":"2005","journal-title":"Cardiovasc. Ultrasound"},{"issue":"6","key":"10.1016\/j.taap.2012.06.007_bb0040","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/cvr\/20.6.444","article-title":"Evaluation of the QA interval as an index of cardiac contractility in anaesthetized dogs: responses to changes in cardiac loading and heart rate","volume":"20","author":"Cambridge","year":"1986","journal-title":"Cardiovasc. Res."},{"issue":"2","key":"10.1016\/j.taap.2012.06.007_bb0045","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0002-8703(05)80018-3","article-title":"Negative inotropic effect of intravenous nifedipine in coronary artery disease: relation to plasma levels","volume":"119","author":"Clifton","year":"1989","journal-title":"Am. Heart J."},{"key":"10.1016\/j.taap.2012.06.007_bb0050","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1046\/j.1472-8206.2002.00081.x","article-title":"In vivo measurement of QT prolongation, dispersion and arrythmogenesis: application to the preclinical cardiovascular safety pharmacology of a new chemical entity","volume":"16","author":"De Clerck","year":"2002","journal-title":"Fund. Clin. Pharmacol."},{"key":"10.1016\/j.taap.2012.06.007_bb0055","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S1056-8719(98)00036-7","article-title":"A pharmacological validation of radiotelemetry in conscious, freely moving rats","volume":"40","author":"Deveney","year":"1998","journal-title":"J. Pharmacol. Toxicol. Methods"},{"issue":"4","key":"10.1016\/j.taap.2012.06.007_bb0060","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11523-011-0203-8","article-title":"Heart to heart with trastuzumab: a review on cardiac toxicity","volume":"6","author":"Di Cosimo","year":"2011","journal-title":"Target. Oncol."},{"key":"10.1016\/j.taap.2012.06.007_bb0065","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.drudis.2008.05.011","article-title":"Cardiotoxicity of the new cancer therapeutics \u2014 mechanisms of, and approaches to, the problem","volume":"13","author":"Force","year":"2008","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.taap.2012.06.007_bb0070","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/jnci\/djm202","article-title":"Effect of pretreatment with atenolol and nifedipine on ZD6126-induced cardiac toxicity in rats","volume":"99","author":"Gould","year":"2007","journal-title":"J. Natl Cancer Inst."},{"key":"10.1016\/j.taap.2012.06.007_bb0075","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/1056-8719(92)90054-5","article-title":"A radiotelemetry system for chronic measurement of blood pressure and heart rate in the unrestrained rat validation of the method","volume":"28","author":"Guiol","year":"1992","journal-title":"J. Pharmacol. Toxicol. Meth."},{"issue":"2","key":"10.1016\/j.taap.2012.06.007_bb0080","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.vascn.2009.07.002","article-title":"Validation of a guinea pig Langendorff heart model for assessing potential cardiovascular liability of drug candidates","volume":"60","author":"Guo","year":"2009","journal-title":"J. Pharmacol. Toxicol. Meth."},{"key":"10.1016\/j.taap.2012.06.007_bb0085","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.vascn.2004.02.006","article-title":"Developing a strategy for the nonclinical assessment of proarrythmic risk of pharmaceuticals due to prolonged ventricular repolarization","volume":"49","author":"Guth","year":"2004","journal-title":"J. Pharmacol. Toxicol. Meth."},{"key":"10.1016\/j.taap.2012.06.007_bb0090","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1034\/j.1399-6576.2003.00046.x","article-title":"Analgesic effect of i.v. paracetamol: possible ceiling effect of paracetamol in postoperative pain","volume":"47","author":"Hahn","year":"2003","journal-title":"Acta Anaesthesiol. Scand."},{"issue":"1","key":"10.1016\/j.taap.2012.06.007_bb0100","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.vascn.2010.05.010","article-title":"An approach to the assessment of drug-induced changes in non-electrophysiological properties of cardiovascular function","volume":"62","author":"Hamlin","year":"2010","journal-title":"J. Pharmacol. Toxicol. Methods"},{"issue":"2","key":"10.1016\/j.taap.2012.06.007_bb0095","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/toxsci\/kfg254","article-title":"QT and RR intervals in conscious and anesthetized guinea pigs with highly varying RR intervals and given QTc-lengthening test articles","volume":"76","author":"Hamlin","year":"2003","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.taap.2012.06.007_bb0105","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0008-6363(00)00310-2","article-title":"Methods of collecting and evaluating non-clinical cardiac electrophysiological data in the pharmaceutical industry: results of an international survey","volume":"49","author":"Hammond","year":"2001","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.taap.2012.06.007_bb0110","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.vascn.2006.05.001","article-title":"ILSI_HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation","volume":"54","author":"Hanson","year":"2006","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.taap.2012.06.007_bb0115","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1476-5381.2011.01415.x","article-title":"Research paper: on the relationship between block of Na+ channel and drug-induced prolongation of the QRS complex","volume":"164","author":"Harmer","year":"2011","journal-title":"BJP."},{"issue":"2","key":"10.1016\/j.taap.2012.06.007_bb0120","first-page":"162","article-title":"Validation of an in vitro contractility assay using canine ventricular myocytes","volume":"260","author":"Harmer","year":"2012","journal-title":"TAAP"},{"issue":"1","key":"10.1016\/j.taap.2012.06.007_bb0125","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.vascn.2005.03.003","article-title":"Cardiovascular parameters in anaesthetized guinea-pigs: a safety pharmacology screening model","volume":"52","author":"Hauser","year":"2005","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.taap.2012.06.007_bb0130","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.vascn.2010.12.004","article-title":"Translation of flecainide- and mexiletine-induced cardiac sodium channel inhibition and ventricular conduction showing from nonclinical models to clinical","volume":"63","author":"Heath","year":"2011","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.taap.2012.06.007_bb0350","author":"ICHE14"},{"issue":"5","key":"10.1016\/j.taap.2012.06.007_bb0140","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/sj.bjc.6604909","article-title":"Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring","volume":"100","author":"Jones","year":"2009","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.taap.2012.06.007_bb0145","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.vascn.2007.03.003","article-title":"Evaluation of the guinea pig monophasic action potential (MAP) assay in predicting drug-induced delay of ventricular repolarisation using 12 clinically documented drugs","volume":"56","author":"K\u00e4gstr\u00f6m","year":"2007","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.taap.2012.06.007_bb0150","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/00005344-200404000-00011","article-title":"Effects of levosimendan and milrinone on oxygen consumption in isolated guinea-pig heart","volume":"43","author":"Kaheinen","year":"2004","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.taap.2012.06.007_bb0155","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/clpt.2010.286","article-title":"Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000\u20132009","volume":"89","author":"Kaitin","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2012.06.007_bb0160","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2307\/2533558","article-title":"Small sample inference for fixed effects from restricted maximum likelihood","volume":"53","author":"Kenward","year":"1997","journal-title":"Biometrics"},{"issue":"4","key":"10.1016\/j.taap.2012.06.007_bb0165","first-page":"188","volume":"1","author":"Knowlen","year":"1973","journal-title":"Cardiac contractility: a review"},{"issue":"Suppl. 9, Suppl. G","key":"10.1016\/j.taap.2012.06.007_bb0355","doi-asserted-by":"crossref","first-page":"G3","DOI":"10.1093\/eurheartj\/sum047","article-title":"The QT interval as it relates to the safety of non-cardiac drugs","author":"Kowey","year":"2007","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.taap.2012.06.007_bb0360","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.vascn.2009.04.173","article-title":"Incidence of cardiac contractility issues in safety pharmacological studies: is the core battery sufficient?","volume":"60","author":"Lain\u00e9e","year":"2009","journal-title":"J. Pharmacol. Toxicol. Methods"},{"issue":"4","key":"10.1016\/j.taap.2012.06.007_bb0180","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1476-5381.2011.01255.x","article-title":"How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?","volume":"163","author":"Laverty","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.taap.2012.06.007_bb0185","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/01.RES.61.1.107","article-title":"Major alterations in relaxation during cardiac hypertrophy induced by aortic stenosis in guinea pig","volume":"61","author":"Lecarpentier","year":"1987","journal-title":"Circ. Res."},{"key":"10.1016\/j.taap.2012.06.007_bb0190","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/(SICI)1096-9861(19990906)411:4<674::AID-CNE11>3.0.CO;2-O","article-title":"Arterial supply of limbic structures in the guinea-pig","volume":"411","author":"Librizzi","year":"1999","journal-title":"J. Comp. Neurobiol."},{"key":"10.1016\/j.taap.2012.06.007_bb0195","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1475-925X-10-5","article-title":"An integrative pharmacological approach to radio telemetry and blood sampling in pharmaceutical drug discovery and safety assessment","volume":"10","author":"Litwin","year":"2011","journal-title":"BioMedical Engineering OnLine."},{"key":"10.1016\/j.taap.2012.06.007_bb0200","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10637-008-9112-9","article-title":"Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors","volume":"26","author":"LoRusso","year":"2008","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.taap.2012.06.007_bb0210","first-page":"121","article-title":"The vertebrobasilar arterial system in the guinea pig as compared with dog and human","volume":"57","author":"Majewska-Michalska","year":"1998","journal-title":"Folia Morphol. (Warsz)."},{"issue":"1","key":"10.1016\/j.taap.2012.06.007_bb0205","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1053-0770(97)90252-4","article-title":"Effects of levosimendan on left ventricular function: correlation with plasma concentrations in conscious dogs","volume":"11","author":"McGough","year":"1997","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"10.1016\/j.taap.2012.06.007_bb0365","author":"Milrinone (Primacor\u00ae) prescribing information"},{"issue":"5","key":"10.1016\/j.taap.2012.06.007_bb0435","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1254\/jjp.32.925","article-title":"Central and peripheral cardiovascular responses of rats to guanabenz and clonidine","volume":"32","author":"Misu","year":"1982","journal-title":"The Japanese Journal of Pharmacology"},{"issue":"1","key":"10.1016\/j.taap.2012.06.007_bb0440","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.vascn.2012.05.008","article-title":"Optimising conditions for studying the acute effects of drugs on indices of cardiac contractility and on haemodynamics in anaesthetized guinea pigs","volume":"66","author":"Mooney","year":"2012","journal-title":"J. Pharmacol. Toxicol. Methods."},{"key":"10.1016\/j.taap.2012.06.007_bb0220","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/nrd2961","article-title":"Lessons from 60years of pharmaceutical innovation","volume":"8","author":"Munos","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.taap.2012.06.007_bb0370","author":"National Archives, UK Animals (Scientific Procedures) Act"},{"issue":"2","key":"10.1016\/j.taap.2012.06.007_bb0230","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.vascn.2009.04.025","article-title":"Correlation between dP\/dtmax and QA interval, two cardiac contractility parameters, in the anaesthetized rat","volume":"60","author":"Ngo","year":"2009","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.taap.2012.06.007_bb0235","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0014-2999(00)00694-4","article-title":"Effects of sparfloxin, grepfloxacin, moxifloxacin and ciprofloxacin on cardiac action potential duration","volume":"406","author":"Patmore","year":"2000","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.taap.2012.06.007_bb0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vascn.2009.08.001","article-title":"A call for more integrated cardiovascular safety assessment","volume":"61","author":"Pettit","year":"2010","journal-title":"J. Pharmacol. Toxicol. Methods"},{"issue":"3","key":"10.1016\/j.taap.2012.06.007_bb0245","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/BF00495866","article-title":"The effect of opiates on arterial baroreceptor reflex function in the rabbit","volume":"319","author":"Petty","year":"1982","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.taap.2012.06.007_bb0250","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1476-5381.2009.00207.x","article-title":"An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk","volume":"159","author":"Pollard","year":"2010","journal-title":"BJP"},{"key":"10.1016\/j.taap.2012.06.007_bb0255","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0008-6363(02)00846-5","article-title":"Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development","volume":"58","author":"Redfern","year":"2003","journal-title":"Cardiovasc. Res."},{"issue":"S1","key":"10.1016\/j.taap.2012.06.007_bb0260","first-page":"1081","article-title":"Impact and frequency of different toxicities throughout the pharmaceutical life cycle","volume":"114","author":"Redfern","year":"2010","journal-title":"Toxicologist"},{"issue":"3","key":"10.1016\/j.taap.2012.06.007_bb0265","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1177\/1091581811398963","article-title":"Cardiovascular function in nonclinical drug safety assessment: current issues and opportunities","volume":"30","author":"Sarazan","year":"2011","journal-title":"Int. J. Toxicol."},{"key":"10.1016\/j.taap.2012.06.007_bb0270","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1177\/1087057102239667","article-title":"IonWorksTM HT: a new high throughput electrophysiological measurement platform","volume":"8","author":"Schroeder","year":"2003","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/j.taap.2012.06.007_bb0275","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1124\/jpet.107.132530","volume":"325","author":"Segreti","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.taap.2012.06.007_bb0280","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1093\/cvr\/27.12.2229","article-title":"Characterisation of NarK-ATPase, its isoforms, and the inotropic response to ouabain in isolated failing human hearts","volume":"27","author":"Shamraj","year":"1993","journal-title":"Cardiovasc. Res."},{"issue":"5","key":"10.1016\/j.taap.2012.06.007_bb0285","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4155\/bio.10.193","article-title":"Evaluation of blood microsampling techniques and sampling sites for the analysis of drugs by HPLC\u2013MS","volume":"3","author":"Smith","year":"2011","journal-title":"Bioanalysis"},{"key":"10.1016\/j.taap.2012.06.007_bb0290","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0165-1838(87)90109-3","article-title":"Autonomic bervous system control of heart rate during baroreceptor activation in conscious and anaesthetized rats","volume":"20","author":"Stornetta","year":"1987","journal-title":"J. Auton. Nerv. Syst."},{"issue":"8","key":"10.1016\/j.taap.2012.06.007_bb0295","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1634\/theoncologist.2010-0432","article-title":"Cardiovascular toxicity profiles of vascular-disrupting agents","volume":"16","author":"Subbiah","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.taap.2012.06.007_bb0300","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/jat.975","article-title":"QT prolongation in anaesthetized guinea-pigs: an experimental approach for preliminary screening of torsadogenicity of drugs and drug candidates","volume":"24","author":"Testai","year":"2004","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.taap.2012.06.007_bb0305","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/jat.1208","article-title":"QT prolongation in guinea pigs for preliminary screening of torsadogenicity of drugs and drug-candidates. II","volume":"27","author":"Testai","year":"2007","journal-title":"J. Appl. Toxicol."},{"issue":"2","key":"10.1016\/j.taap.2012.06.007_bb0375","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/eurjhf\/hfr165","article-title":"Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge","volume":"14","author":"Tocchetti","year":"2012","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.taap.2012.06.007_bb0315","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1254\/jphs.QT-A2","article-title":"QT PRODACT: In vivo QT assay in the conscious dog for assessing the potential for QT interval prolongation by human pharmaceuticals","volume":"99","author":"Toyoshima","year":"2005","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.taap.2012.06.007_bb0320","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.vascn.2008.05.007","article-title":"Safety and secondary pharmacology: successes, threats, challenges and opportunities","volume":"58","author":"Valentin","year":"2008","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.taap.2012.06.007_bb0325","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1152\/ajplegacy.1963.205.1.30","article-title":"Hemodynamic determinants of the maximal rate of rise of left ventricular pressure","volume":"205","author":"Wallace","year":"1963","journal-title":"Am. J. Physiol."},{"issue":"7","key":"10.1016\/j.taap.2012.06.007_bb0330","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/bjp.2008.267","article-title":"Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model","volume":"154","author":"Yao","year":"2008","journal-title":"BJP"},{"key":"10.1016\/j.taap.2012.06.007_bb0335","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1213\/01.ane.0000216290.74626.27","article-title":"A comparison of three phosphodiesterase type III inhibitors on mechanical and metabolic function in guinea pig isolated hearts","volume":"102","author":"Zausig","year":"2006","journal-title":"Anesth. Analg."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X12002669?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X12002669?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T22:48:44Z","timestamp":1551912524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X12002669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":69,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0041008X12002669"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2012.06.007","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}